Drug Guidance
Atogepant and rimegepant for prophylaxis of migraine
Condition
Neurology
4 June 2025
-
Published on 04 Jun 2025
Last Updated on 04 Jun 2025
Guidance Recommendations
The Ministry of Health’s Drug Advisory Committee has not recommended the following medications for inclusion on the MOH List of Subsidised Drugs, due to their uncertain comparative clinical effectiveness and substantially higher prices versus subsidised alternatives:
Atogepant for prophylaxis of chronic migraine; and
Atogepant or rimegepant for prophylaxis of episodic migraine.
Atogepant and rimegepant for prophylaxis of migraine [PDF, 674 KB]
PES_Atogepant and rimegepant for preventing migraine (Published 4 Jun 2025) [PDF, 77 KB]